Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapyPierre Savi, Jean‐Marc Herbert, J P Hérault et al.|Journal of Thrombosis and Haemostasis|2008Cited by 64
Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of AntithrombinMieke Dewerchin, Jean‐Marc Herbert, Jean-Pascal Hérault et al.|Circulation Research|2003Cited by 27
5-Chlorothiophene-2-carboxylic Acid [(<i>S</i>)-2-[2-Methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a Selective and Potent Orally Active Dual Thrombin and Factor Xa InhibitorJérôme Meneyrol, Jean‐Marc Herbert, Frédéric Petit et al.|Journal of Medicinal Chemistry|2013Cited by 25
Antithrombotic Properties of SSR182289A, a New, Orally Active Thrombin InhibitorJ Lorrain, Stephen E. O'Connor, L. Millet et al.|Journal of Pharmacology and Experimental Therapeutics|2003Cited by 23
Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivoJ-P. Hérault, J‐M. Herbert, M. Cappelle et al.|Journal of Thrombosis and Haemostasis|2003Cited by 14